EP2629848B1 - Ultraschall-transceiver und steuerung eines wärmeschadensprozesses - Google Patents
Ultraschall-transceiver und steuerung eines wärmeschadensprozesses Download PDFInfo
- Publication number
- EP2629848B1 EP2629848B1 EP11782223.9A EP11782223A EP2629848B1 EP 2629848 B1 EP2629848 B1 EP 2629848B1 EP 11782223 A EP11782223 A EP 11782223A EP 2629848 B1 EP2629848 B1 EP 2629848B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- signal
- transceiver
- ultrasonic
- frequency
- excitation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 30
- 230000008569 process Effects 0.000 title description 12
- 238000002604 ultrasonography Methods 0.000 title description 9
- 230000003685 thermal hair damage Effects 0.000 title description 5
- 230000005284 excitation Effects 0.000 claims description 56
- 230000001427 coherent effect Effects 0.000 claims description 37
- 238000002679 ablation Methods 0.000 claims description 33
- 238000002592 echocardiography Methods 0.000 claims description 33
- 238000012544 monitoring process Methods 0.000 claims description 22
- 230000006870 function Effects 0.000 claims description 21
- 238000012935 Averaging Methods 0.000 claims description 17
- 238000001228 spectrum Methods 0.000 claims description 17
- 238000002955 isolation Methods 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 9
- 238000013459 approach Methods 0.000 claims description 8
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 8
- 238000012886 linear function Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000010349 pulsation Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 241001463014 Chazara briseis Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 238000011298 ablation treatment Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000010358 mechanical oscillation Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00106—Sensing or detecting at the treatment site ultrasonic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B2017/22027—Features of transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/320068—Surgical cutting instruments using mechanical vibrations, e.g. ultrasonic
- A61B2017/320069—Surgical cutting instruments using mechanical vibrations, e.g. ultrasonic for ablating tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/12—Arrangements for detecting or locating foreign bodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/504—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of blood vessels, e.g. by angiography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
- A61F2007/0063—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit for cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/09—Guide wires
- A61M2025/091—Guide wires having a lumen for drug delivery or suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/0026—Stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0039—Ultrasound therapy using microbubbles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0082—Scanning transducers
Definitions
- the present invention in some embodiments thereof, relates to an ultrasound transceiver and to control of an ablation or thermal damage process to a tissue and, more particularly, but not exclusively, to use of the transceiver in simultaneous monitoring and ablation of nearby tissue by monitoring the distance to the tissue walls, and use of change in distance between tissue walls as an indicator of progress of the thermal damage.
- a damped receiver For the purpose of detection of effects, a damped receiver is desirable, since without damping, ringing occurs, making signals hard to read.
- the problem is to detect the wall of an artery, or any other tissue, using an ultrasonic transceiver which is also performing the ablation and which thus must be undamped because damping will reduce efficiency. Low efficiency leads to increased heating, which can be harmful in confined spaces such as blood vessels.
- the signal from the artery wall is drowned out by noise due to ringing and the primary echo is hard to discern. Nevertheless, detecting the echo is highly desirable in order to monitor the ablation treatment.
- An embodiment of the present invention may analyze a sequence of sample signals.
- the primary echo has a fixed relationship to the excitation signal, whereas the ringing signals do not.
- the primary echo shares a main frequency component with the excitation signal although not the phase and not the amplitude. The relationship is used to distinguish the primary echo from ringing and from secondary echoes.
- an ultrasonic transceiver apparatus for intracorporeal use comprising:
- the signal processor is configured with an instantaneous frequency estimator to obtain an envelope of received signal minus excitation signal from the undamped ultrasonic transceiver and to use a global phase and local slopes thereof as an estimate of the instantaneous frequency, and further comprising an isolator unit for isolating signal segments whose instantaneous frequency approaches the characteristic frequency as segments containing primary echoes.
- An embodiment may comprise a window unit for windowing the received signal using a windowing length chosen to provide windows with an expectation of a single primary echo.
- the signal processor is further configured to find a point of appearance of a primary echo in a received signal by successively dividing the curve and fitting to a linear functions and calculating a point at which a corresponding error function is minimized.
- An embodiment may be configured with a location unit to determine a distance to a first feature wall from the point of appearance.
- the location unit is configured to use a second point of appearance of a further primary echo to determine a distance to a second feature wall
- the signal processor further comprising a monitoring unit for monitoring a distance between the first feature wall and the second feature wall as an indicator of ablation progress.
- the signal processor comprising a convolution unit for convolving an excitation signal with the received signal to carry out the isolation of the primary echo.
- the signal processor comprises a Fourier component analyzer for isolating segments having a principle Fourier component which corresponds to a body-characteristic frequency.
- the signal processor comprises a coherent summation unit for carrying out data summation such as to preserve amplitude and shift signals to a same phase.
- the coherent summation unit is configured to perform coherent summation, the coherent summation comprising building an auxiliary matrix of phase weights, making a Hilbert transform and multiplying to bring all the signal to the same phase, therewith to create an in-phase sum.
- An embodiment may comprise a reference subtracting unit configured to subtract a reference from the transceiver signal by averaging several signal samples to eliminate unstable component.
- an ultrasonic transceiver method for intracorporeal use comprising:
- the isolation comprises obtaining an envelope of received signal minus excitation signal from the undamped ultrasonic transceiver and using a global phase and local slopes as an estimate of the instantaneous frequency, and isolating those signal segments whose frequency approaches the instantaneous excitation frequency.
- An embodiment may comprise windowing the received signal using a windowing length chosen to provide windows with an expectation of a single primary echo.
- An embodiment may comprise determining a distance to a first feature wall from the point of appearance.
- An embodiment may comprise using a second point of appearance of a further primary echo to determine a distance to a second feature wall, and monitoring a distance between the first feature wall and the second feature wall as an indicator of ablation progress.
- An embodiment may comprise convolving an excitation signal with the received signal to carry out the isolation of the primary echo.
- An embodiment may comprise isolating segments having a principle Fourier component which corresponds to a body characteristic frequency.
- An embodiment may comprise carrying out coherent data summation such as to preserve amplitude and shift signals to a single phase.
- the coherent summation comprises:
- an ultrasonic transceiver apparatus for intracorporeal use, the apparatus comprising:
- the body characteristic frequency may be pulse or breathing rate.
- the signal processor is configured to obtain a power spectrum of a signal extracted from the transceiver and to identify the primary echoes from peaks in the power spectrum at the body-characteristic frequency.
- An embodiment may comprise a coherent summation unit or a convolution unit or both.
- a method of providing controlled thermal damage to a tissue comprising:
- the monitoring and applying are carried out from within a blood vessel, and/ or using ultrasonics.
- a known ablation device may be used in conjunction with an ultrasonic detector.
- Implementation of the system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of embodiments of the system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.
- a data processor such as a computing platform for executing a plurality of instructions.
- the data processor includes a volatile memory for storing instructions and/or data and/or a non-volatile storage, for example, a magnetic hard-disk and/or removable media, for storing instructions and/or data.
- a network connection is provided as well.
- a display and/or a user input device such as a keyboard or mouse are optionally provided as well.
- the present invention in some embodiments thereof, relates to an ultrasound transceiver, in particular for use in confined spaces such as blood vessel to carry out self-monitored ablation on surrounding tissues.
- the problem is to detect the wall of an artery (or any other tissue) using an ultrasonic detector which must be undamped because damping will reduce efficiency.
- the effectiveness of an ablation process can be determined by measuring the distance between outer and inner walls of a tissue being ablated. Specifically, as the tissue is ablated, the distance between the outer and inner walls falls, so sequential monitoring of the distance is a way of measuring the effectiveness of the ablation process.
- the issue is that the signal from the artery wall is drowned out by noise and the ringing.
- the primary ringing tends to share a main frequency with the excitation signal, although the phase will differ depending on the distance.
- the frequency can be used to distinguish primary echoes from ringing and from secondary echoes as well as general noise.
- detecting the primary echoes allows them to be used in an analysis of the entire artery wall tissue signal, and not only the face of the wall that is touching the blood.
- the transceiver Since the transceiver is a narrow band device, it irradiates mainly at its Eigen frequency. Furthermore, voltages generated by returned pressure waves are again filtered by the transceiver, so that the primary reflected signal is an almost pure harmonic oscillation, albeit with variable amplitude. It is reasonable to expect that transient-only portions of the signal are characterized by different frequencies.
- the present embodiments further include a means of providing controlled thermal damage to a tissue, by identifying locations of boundary walls of the tissue, applying energy to the tissue, and monitoring changes in locations of the boundary walls as indicators of the application of energy to the tissue, for example thermal shrinkage of the tissue; Then the application of the thermal energy can be controlled y according to the detected effect.
- the monitoring and applying are carried out from within a blood vessel, and/ or using ultrasonics.
- the above may be carried out using the transceiver described herein but alternatively, a known ablation device may be used in conjunction with an ultrasonic detector.
- the effect on the tissue is not necessarily shrinkage. It may instead be thickening due to heating or to some physiological response. Nevertheless it is the change in size or shape of the tissue, as determined by changes in tissue wall location determined by non-imaging or imaging of tissue, that is used to control the process.
- the present embodiments relate to non-focused ultrasound, or to focused ultrasound or to r.f. based systems.
- FIG. 1 illustrates an ultrasonic transceiver apparatus 10 primarily intended for intracorporeal use, according to one embodiment of the present invention.
- a transceiver 12 is designed to be injected into blood vessels and like confined spaces within the body, particularly with a view to flowing towards locations where tissue ablation is required, and to direct ultrasound energy towards the tissue to be ablated. In between ablations the transceiver is excited with monitoring signals to use ultrasound energy for a different purpose, the monitoring of the surrounding tissues to make sure that the ablation is being carried out effectively.
- the transceiver is required to be as efficient as possible and thus to be undamped. Monitoring however requires a damped transceiver since reading the echoes is conventionally only possible once the excitations have died down. Using different transceiver surfaces for monitoring and ablation respectively is also not ideal since it is difficult to guarantee that the tissue being monitored is the same as the tissue being ablated.
- the present embodiments thus use a single undamped transceiver for both monitoring and ablation. Structures are provided for isolating the primary reflections from ringing due to the excitation signal and due to secondary reflections from the ringing as well as assorted other noise.
- the undamped ultrasonic transceiver may be a narrow band transceiver having a characteristic excitation frequency so that all excitations are at that characteristic frequency.
- the primary echoes tend to share the excitation frequency, albeit at variable phases and amplitudes, whereas general ringing and tend to be at other g frequencies.
- a signal processor 14 is connected to the transceiver 12 to isolate the primary echo signals from the ringing, secondary echoes and extraneous noise also received from the transceiver.
- the signal processor uses presence or absence of the characteristic frequency as an isolation criterion.
- An excitation unit 16 provides an excitation signal for the transceiver.
- the excitation may be high power for the ablation or low power for monitoring.
- the signal processor may have reference subtraction unit 18 which subtracts the excitation signal, from the transceiver 12.
- the size of the segments may be chosen so that only one primary echo need be found per segment. Otherwise the presence of multiple reflections makes analysis more difficult.
- the distances between tissue walls are known in general terms so segment lengths are chosen to represent distances smaller than the distance between walls.
- a window unit 22 windows the received signal using a windowing length chosen to provide segments with an expectation of a single primary echo.
- segment isolator can find primary echoes.
- a convolution unit 20 convolves an excitation signal with the received signal to isolate only those waveforms having a high coherence with the excitation signals.
- a coherent summation unit 27 carries out data summation such as to preserve amplitude and shift signals to the same phase.
- the coherent summation unit may build an auxiliary matrix and then multiplies it with previously carried out Hilbert transform to shift the obtained complex analytic signals to the same phase and to make in-phase (coherent) summation
- Coherent summation is discussed in greater detail below.
- Fig. 4 discusses double coherent summation and convolution as a way to obtain the primary echoes.
- Reference subtracting unit 18 may subtract a reference from the transceiver signal by averaging several signal samples (particular records), simply to eliminate unstable components and obtain the actual excitation.
- a separate reference signal is known to be free of echoes in the region of interest. Thus, its subtraction from the particular signal reliably provides us with almost pure echo, except for the noise component.
- the signal processor may find a point of appearance of a primary echo in the segment by successively dividing the envelope curve while fitting to a linear function and calculating a point at which a corresponding error function is minimized. Such a process is illustrated in Fig. 6 below.
- the point of error minimization is most probably the point of onset of the primary echo and indicates the distance to a structure such as a tissue wall. Such an error minimization is shown in Fig. 7 discussed below.
- a location unit 24 determines the distance to a first feature wall based on the point of appearance.
- the location unit may then use a second point of appearance of a further primary echo to determine a distance to a second feature wall.
- a process monitoring unit then calculates and monitors the distance between the first feature wall and the second feature wall as an indicator of ablation progress. As the ablation progresses the wall typically shrinks as the tissue dries out.
- the signal processor uses correlation with a body-characteristic frequency as an isolation criterion.
- a body-characteristic frequency is to obtain a power spectrum of the signal extracted from the transceiver and to identify the primary echoes from peaks in the power spectrum at the body-characteristic frequency.
- the Fourier component analysis may be used instead of or in addition to coherent summation and to convolution using a convolution unit.
- an envelope of the oscillating signal is obtained, and a global phase and its local slopes are used as estimations of instantaneous frequency (actually, instantaneous frequency is local slope itself). Also instantaneous frequency is estimated from the entire signal in analytical form, as time derivative of phase. The appearance of a primary reflection signal is then recognized within the overall envelope as a transition at an instantaneous frequency of the signal.
- the transceiver frequency remains constant.
- the Hilbert transform is carried out on a residual signal, after reference subtraction. The results are used for coherent summation of original signals. signal construction the Hilbert transform effectively creates a signal shifted by a quarter of a period with respect to the original signal. For a true harmonic signal, the phase of the obtained complex analytic signal - see Fig. 5B , grows linearly in time. If a new harmonic component appears in the signal, it may be revealed by a change of the phase - time curve slope.
- a new harmonic component may be taken as the indication of a new feature that is being detected, say the near surface of a tissue in question, and a second new harmonic component may indicate the far surface of the tissue in question artery wall.
- an algorithm for minimum total error may be used. As illustrated in Fig. 6 , the entire curve may be divided in two parts and each part may then be fitted to a linear function. We consider double fitting of the entire error as a function of the separation point. The assumption is that for the true separation point between two frequency regions the overall error reaches its minimum. In general, a change in best slope indicates the appearance of a new event. The point where the new harmonic is added turns out to be derivable from the error function. The overall error of the two curve fitting operations is a function of the point of appearance of the new harmonic, and minimization of the overall error may indicate the point. Fig. 7 illustrates such an error function with a clear minimization point.
- the excitation voltage generates mechanical oscillations in the transceiver, which irradiate pressure waves into surrounding media. Return pressure waves generate a reflection voltage signal. It is reasonable to expect that the reflection retains at least a partial correlation with the excitation voltage.
- An alternative or additional approach is just to convolve part of the excitation signal with the rest of the data. The reflection may thus be amplified according to the correlation and become more recognizable.
- Fig. 8 illustrates local slopes of a phase-distance curve. Over the full phase - time (distance) curve one can evaluate local standard statistical parameter correlation coefficients. For perfectly linear dependence between two values the correlation coefficient is ⁇ 1. For noisy data or for nonlinear dependence, the absolute value is less than 1. A stable and significant decrease of correlation coefficient serves as a reliable sign of useless noisy data and allows the irrelevant signal to be excluded.
- correlation coefficients can thus be used to find parts of the data where there are strong echoes and ignore parts where such strong echoes are absent.
- the present embodiments were applied experimentally to estimate distance within the interval 0.19 - 5.19 mm.
- in vitro experiments it is possible to control distance between transceiver and reflective object (metal plate) by means of a positioning device with a ruler and set it in parallel to the transceiver surface. Accuracy of 0.1 mm is available.
- in vitro experimentation is used to generate a calibration curve between measured and actual distances. That is, to the experiment finds slope and intercept. The slope is expected to be close to 1. The intercept allows for elimination of systematic error in the ruler reading. Indeed, the intercept is not the interesting point, although technically necessary.
- the indication of evaluation correctness is that the evaluated points lie on a straight line with a slope close to 1.
- the sample equivalent is a reciprocal sampling frequency. For 800 MHz, it is 1.25 ns.
- the sample equivalent is half of the sampling period multiplied by sound velocity. Its interpolated value at 23° C is 1489 m/s. Thus, a distance equivalent is 9.306-10-4 mm.
- Fig. 2 upper part presents a raw signal and the lower part shows the same after reference subtraction.
- Fig. 3 upper part shows averaging and gives a ratio of maximum amplitude over noise standard deviation to be 5.86.
- the signal shown represents results of averaging 11 particular signals.
- the lower part of Fig. 3 shows coherent summation and manages to achieve a ratio of maximum amplitude over noise standard deviation of 10.2, nearly double the level achieved by averaging.
- the best improvement of SNR for 11 particular signals is 3.32. It follows from Fig. 3 that the real improvement is 1.74. Specifically, the improvement is the ratio of SNRs after and before processing. SNR after processing is 10.2, and SNR before is 5.96. SNR after processing is greater.
- Figures 5A - 8 are as discussed above and illustrate estimated and real distance results for distances of 0.19mm or 0.69mm.
- Fig. 5A shows the raw signal and
- Fig. 5B shows the corresponding analytical signal.
- Fig. 6 shows the curve fitting to find the point at which the primary echo component appears.
- Fig. 7 illustrates the error function and
- Fig. 8 illustrates the full phase-distance curve from which local slopes can be obtained.
- Figures 9A - 12 illustrate corresponding estimated and real distance data for a distance of 1.19mm.
- Fig. 9A shows the raw signal and
- Fig. 9B shows the corresponding analytical signal.
- Fig. 10 shows the fitting.
- Fig. 11 illustrates the error function and
- Fig. 12 illustrates the full phase-distance curve.
- Figs 13A - 16 illustrate results for a distance of 1.69mm.
- Fig. 13A shows the raw signal and
- Fig. 13B shows the corresponding analytical signal.
- Fig. 14 shows the fitting.
- Fig. 15 illustrates the error function and
- Fig. 16 illustrates the full phase-distance curve.
- Figs 17 - 20 illustrate results for a distance of 2.19mm.
- Fig. 17A shows the raw signal and Fig. 17B shows the corresponding analytical signal.
- Fig. 18 shows the fitting.
- Fig. 19 illustrates the error function and Fig. 20 illustrates the full phase-distance curve.
- Figs 21A - 24 illustrate results for a distance of 2.69mm.
- Fig. 21A shows the raw signal and
- Fig. 21B shows the corresponding analytical signal.
- Fig. 22 shows the fitting.
- Fig. 23 illustrates the error function and
- Fig. 24 illustrates the full phase-distance curve.
- Figs 25A - 28 illustrate results for a distance of 3.19mm.
- Fig. 25A shows the raw signal and Fig. 25B shows the corresponding analytical signal.
- Fig. 26 shows the fitting.
- Fig. 27 illustrates the error function and Fig. 28 illustrates the full phase-distance curve.
- Figs 29A - 32 illustrate results for 3.69mm.
- Fig. 29A shows the raw signal and Fig. 29B shows the corresponding analytical signal.
- Fig. 30 shows the fitting.
- Fig. 31 illustrates the error function and Fig. 32 illustrates the full phase-distance curve.
- Figs 33A - 36 illustrate results for a distance of 4.19mm.
- Fig. 33A shows the raw signal and
- Fig. 33B shows the corresponding analytical signal.
- Fig. 34 shows the fitting.
- Fig. 35 illustrates the error function and
- Fig. 36 illustrates the full phase-distance curve.
- Figs 37A - 40 illustrate results for a distance of 4.69mm.
- Fig. 37A shows the raw signal and
- Fig. 37B shows the corresponding analytical signal.
- Fig. 38 shows the fitting.
- Fig. 39 illustrates the error function and
- Fig. 40 illustrates the full phase-distance curve.
- Figs 41A - 44 illustrate the results for a distance of 5.19mm.
- Fig. 41A shows the raw signal and
- Fig. 41B shows the corresponding analytical signal.
- Fig. 42 shows the fitting.
- Fig. 43 illustrates the error function and
- Fig. 44 illustrates the full phase-distance curve.
- a correlation curve is obtained by fitting measured results to actual distances.
- a straight line is fitted to the data points, with slope 0.89 and intercept 0.18 mm. Correlation of known and estimated distances is high, and the observed correlation coefficient is 0.9954.
- the procedure is now considered in more detail. It is required to estimate distance from a transceiver surface to artery wall.
- the range of interest lies between 1...5 mm. Allowed error is 0.2 mm. Processing time is not intended to exceed 2s.
- the reflected signal is typically small. That is, first, it is corrupted by noise in general and, second, is distorted by a residual excitation signal, otherwise known as ringing. As mentioned, the ringing can produce second order effects such as echoes of the ringing.
- the reflected signal is a superposition of multiple similar signals each produced by its own source the source. That is, the shape of reflected signal may vary depending on the angular position of the transceiver.
- applied transceivers are narrow band devices and reflected signals are close to harmonic, however, with variable amplitude. This allows for efficient signal isolation.
- Data are built as a matrix, whose columns represent a reaction wherein a single record maps to a single pulse. Then, columns of the records are divided into groups on which averaging is carried out. Following this, each column is processed on the basis of the averaged groups and overall results are averaged.
- row size may represent the total number of points recorded in a single echo response, and the column numbers may represent the total number of echo responses which was recorded.
- a reference signal is obtained by averaging of several records.
- phases of reflected signals are randomly different from each other, and averaging weakens this component.
- the excitation pulse is taken as stable so averaging does not cause any deterioration.
- the unstable component is more or less efficiently eliminated from the processed signal.
- Noise levels may be estimated from a remote part of a record where reflections are not expected.
- the procedure identifies the primary echo based on coherent summation.
- a set of signals which are expected to be similar to each other. Ideally, all signals would be the same, except for the noise component. Thus summation of N such signals increases the entire signal N times while noise increases only N times. As a result, the SNR improvement is N times.
- the described procedure becomes less efficient. This can be solved by means of a Hilbert transform producing a complex analytic signal, in which each signal can be assigned a phase, which, for a true harmonic signal would be the true phase.
- the denominator provides proper normalization such that entries of the above weights matrix are true phase exponents.
- the upper index H means matrix Hermit conjugation (or Hermitian conjugation), which is transposition together with complex conjugation.
- a first factor in equation 3 is the analytic signal corresponding to the entire set of signals.
- a second factor is an auxiliary phase weight matrix, which provides summation with proper phases.
- S3 Reference subtraction.
- individual subtraction is used. That is to say, for each set of data, the reference signal is multiplied by an individual scaling factor which is close to 1. The scaling factor is evaluated using the initial portion of data (below 1 mm). Individual scaling factors provide the least RMS error being applied to a particular signal, but to a portion, which is not involved in further processing. In the present embodiments, these values are propagated to the remaining portion of the data for more efficient subtraction of the excitation signal. z ⁇ z - z ref .
- S4 Averaging. Each group of columns is averaged. Members of the group participate in the coherent summation procedure. In an embodiment, an optimal arrangement of groups is used. In this arrangement, within each group, phases are closer to each other.
- S7 Actual transceiver frequency evaluation.
- S8 is shown in greater detail in Fig. 47 .
- phase curve is divided into small pieces (about 100 samples), and for each piece a local strip and a normalized linear fitting error are evaluated.
- local slopes are obtained on overlapping pieces.
- An instantaneous frequency may be found at each point.
- instantaneous frequencies may be obtained by usage of a formally exact definition of frequency as a phase time derivative.
- a Hilbert transform of the derivative may be involved.
- a first factor in the above is a standard windowing factor (Hanning, Gauss, Kaiser, etc.).
- a size of the window may correspond to 2 periods.
- This second definition is used when the noise level is found to be too high. Sometimes extremely stretched signals are observed. Dimensionless factors in these formulas are established based on visual analysis of the processed signal and may be subjected to fine tuning.
- reflected signals start at a relatively high level and do not fall below a threshold. Such would be an indication that the origin is closer than 0.95 mm.
- SNR max A ⁇ noise .
- Fig. 1 presents a raw signal and the same after reference subtraction.
- Fig. 2 presents results of just averaging 11 particular signals vs. coherent summation.
- the best improvement of SNR for 11 particular signals is 3.32. It follows from Fig. 3 that the real improvement is 1.74 based on the SNR values shown and as discussed above.
- Figs. 48 - 51 illustrate an approach based on grouping of samples according to relationships between the echo signals, body frequencies such as pulse or breathing, and the original excitation.
- the relative position of tissues within the body changes over short times due to breathing and blood pulsation.
- Ultrasonic echoes from tissues obey such a periodicity whereas ringing artifacts and other types of noises do not. This is specifically true for ultrasonic echoes measured intravascularly. Consequently, the existence of such periodicity can be utilized to separate between tissue reflection and other noise sources in echoes with low signal to noise ratio.
- Figure 48 (upper left part) shows the echo response of consecutive trials as a function of distance. A clear periodic change in the echo response from the tissue is observed.
- the characteristic frequency profiles due to tissue movement are used to separate between the characteristic frequencies and ringing artifacts and other noise signals.
- the catheter moves at similar frequencies to the blood pressure, as illustrated in the right part of Fig. 48 .
- the echo readings due to catheter ringing as well as other noises are not influenced by the blood pulsation.
- the echo signal distance can be distinguished from the background by the fact that it moves backward and forward in correspondence to the blood pulsation.
- separating the signals that show the periodicity of the blood pressure movement from other noises may help to identify primary tissue echoes even though their signal to noise ratio is low. This allows accurate detection of the distance to the tissue wall.
- consecutive echo signals are first collected and the power spectrum is calculated for every point in the echo along consecutive trials. This is illustrated in figure 49 which shows the power spectrum of each point of the echo. Each point corresponds to a different distance.
- the power spectrum intensity is color coded from blue to red.
- the ratio between the frequency components of breathing and blood pulsation, which were estimated as described earlier, and the frequency components of noise and ringing are calculated for each point of the echo signal.
- the response ratio is defined as the reflection profile and is used to separate tissue reflections from other noises.
- Fig. 50 The results of such a process are illustrated in Fig. 50 .
- the upper part of Fig. 50 shows 256 consecutive echo trials as a function of distance. Echo intensity is color coded from blue to red.
- the middle part shows five superimposed individual trials.
- the variability profile between different signals during the ringing is different from the variability during reflections. These changes in variability are reflected in the power spectrum over consecutive echoes.
- the lower part of Fig. 50 is a plot of the reflection profile (in blue).
- a smoothed reflection profile (green) is obtained using a median filter.
- a rise in this profile indicates reflections from the tissue due to increase in frequencies associated with blood pressure and breathing.
- the distance from the artery can be identified using a threshold crossing of the smoothed reflection intensity function, the green line in Fig 50 .
- the threshold is automatically detected by analyzing the spectrum of points with no tissue reflections, which points are detected using their low kurtosis values.
- Fig. 51 a summary of the procedure to achieve the above is as follows: Firstly, in 51.1, the power spectrum analysis over the same sample in consecutive echos is performed. In the given example ( Fig 50 ), the echo signal is recorded 256 times, to form 256 records at a sampling frequency of 400 Hz. Within each record, 10000 points are sampled at 800 MHz.
- a power spectrum is calculated for each point over the 256 consecutive trials, giving 10000 power spectrum graphs each being 256 samples in length.
- the reflection intensity of every point is calculated by using the freq. ratio between the blood pressure frequencies and noise frequencies at each point (S51.2).
- Tissue reflections are identified by their high reflection intensity (S51.3).
- the tissue wall location is identified using an automatically detected threshold.
- Reliable measurement may require transceiver - tissue boundary distances which are greater than 1 mm and up to 5 mm.
- Signal acquisition is performed at 800 MHz/14 bit, and with a suitable oscilloscope such as that produced by AgilentTM, the sampling rate may be increased to 2 GHz, but at a modest 8 bit resolution.
- transceiver characteristic frequency about 10 and 20 MHz, time resolution is 80 - 40 samples per period.
- PRF 400 Hz which for 1000 repetitions constitutes a measurement duration of 2.5 s. This is enough to observe at least one entire period of heart pulse and therefore a full cycle of an artery dilating and shrinking. This linkage may facilitate distance measurement. In the experiments above there was processing of only 256 repetitions, using about 9000 samples each. At a PRF of 80 kHz, the entire measurement may take 3.2 ms. This time is too short for significant changes in mutual orientation of transceiver and tissue boundary, or distance between the transceiver and tissue boundary, and thus is expected to improve accuracy. In addition, a long acquisition process provides mutual incoherence of reflected signals which weakens the reflected signal level in the reference.
- the transceivers are narrow band. Their advantage is that the main component of their signal is at the Eigen frequency at different excitation shapes. Reflected signal appearance is seen clearly using the Hilbert transform and direct evaluation of local slopes of the phase - time curve. Another possibility is to create a Hilbert transform based instantaneous frequency. A special excitation shape may shorten transient reaction and therefore decrease the low measurement limit.
- an Eigen frequency is supplied for the transceiver, it is reasonable to make a data-based estimation. Due to variable amplitude, an instantaneous frequency may change within certain limits even for a pure single-frequency signal. Thus, the frequency may be found from local slopes, which fall within predefined tolerances of the transceiver (say, ⁇ 15%) and provide the smallest linear fitting errors. Parts of the data subjected to coherent summation are those which correspond to points which have a frequency that is close to the nominal transceiver frequency. Optionally, all entries of the instantaneous frequency matrix can be subjected to a logical operation which returns true if the frequency falls within the predetermined tolerances and false otherwise. A summation over the rows indicates how suitable a current point may be for coherent summation, and then a predetermined number of the points with largest sums are taken for coherent summation. A resonant window may then amplify true frequency components.
- Phase correction of particular signals that is bringing all signals of interest to the same phase, allows improvement in the SNR.
- the obtained signal is convolved with a resonant window.
- groups may be arranged such that, within each group mutual closeness is better.
- the above processing algorithm may provide a rapidly growing envelope signal. Since the slope is large, an error due to uncertainty of the threshold (signal appearance above noise) decreases.
- the results of processing may show some cases of multiple reflections, which do not look as though they are reflections from the same object. It is likely that there are different objects with different reflecting properties.
- the algorithm of the present embodiments provides a relative height and a length with each peak. The present embodiments may additionally help to classify/recognize detected objects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Mechanical Engineering (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Surgical Instruments (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Dentistry (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (15)
- Ultraschall-Transceiver zur innerkörperlichen Verwendung, umfassend:einen ungedämpften Ultraschall-Transceiver, geeignet um in einen begrenzten innerkörperlichen Raum platziert zu werden, wobei der Transceiver eine charakteristische Frequenz aufweist und geeignet ist, Erregung bei der charakteristischen Frequenz zu empfangen, um einen Ablösestrahl zum Ablösen von umgebenden Gewebe zu erzeugen, und ferner geeignet ist, Erregung durch primäre Echosignale, zurückkommend von dem umgebenden Gewebe, zu empfangen;gekennzeichnet durch einen Signalprozessor, verbunden mit dem Transceiver, konfiguriert zum Isolieren der primären Echosignale von Lauten, sekundären Echos und belanglosen Geräuschen, ebenfalls von dem Transceiver empfangen, wobei der Signalprozessor eine Korrelation mit einer körpercharakteristischen Frequenz als Isolationskriterium verwendet.
- Vorrichtung nach Anspruch 1, wobei die körpercharakteristische Frequenz ein Mitglied der Gruppe, bestehend aus Impuls und Atmungsrate, ist.
- Vorrichtung nach Anspruch 1, wobei der Signalprozessor konfiguriert ist, ein Leistungsspektrum von einem Signal, extrahiert von dem Transceiver zu erhalten, und die primären Echos von Spitzen in dem Leistungsspektrum bei der körpercharakteristischen Frequenz zu identifizieren.
- Vorrichtung nach Anspruch 1, ferner umfassend eine kohärente Summierungseinheit.
- Vorrichtung nach Anspruch 1, ferner umfassend eine Windungseinheit.
- Ultraschall-Transceiver-Vorrichtung nach Anspruch 1, umfassend:Schaltkreise zum Identifizieren der Lage von Begrenzungswänden des Gewebes; und zum Überwachen von Lageveränderungen der Begrenzungswände als Indikatoren für eine Auswirkung der Energie auf das Gewebe; undzum Steuern der Anwendung von Energie auf das Gewebe entsprechend der Auswirkung.
- Ultraschallvorrichtung nach Anspruch 1, umfassend Schaltkreise zum Erregen des Transceivers bei einer Momentanerregungsfrequenz, um einen Ultraschall-Ablösungsstrahl zum Ablösen von umgebendem Gewebe unter Verwendung von Ablösungsimpulsen zu erzeugen; und
in Intervallen zwischen den Ablösungsimpulsen eine Überwachung der Erregung bereitzustellen, um primäre Echosignale, zurückkommend von dem umgebenden Gewebe, auszulösen. - Ultraschall-Transceiver-Vorrichtung nach Anspruch 1, wobei der Transceiver eine Momentanerregungsfrequenz hat und zum Empfangen von Erregung bei der Erregungsfrequenz, um den Ultraschall-Ablösungsstrahl zum Ablösen des umgebenden Gewebes zu erzeugen; und wobei der Signalprozessor die Anwesenheit oder Abwesenheit der Momentanerregungsfrequenz als ein Isolationskriterium verwendet.
- Ultraschall-Transceiver-Vorrichtung nach Anspruch 8, wobei der Signalprozessor mit einem Momentanfrequenzkalkulator konfiguriert ist, um eine Amplitude von empfangenem Signal minus Erregungssignal von dem ungedämpften Ultraschall-Transceiver zu erhalten und eine globale Phase und ein lokales Gefälle davon als eine Schätzung der Momentanfrequenz zu erhalten, und ferner umfassend eine Isolatoreinheit zum Isolieren von Signalsegmenten, deren Momentanfrequenz sich der charakteristischen Frequenz als Segmente enthaltende primäre Echos annähert.
- Ultraschall-Transceiver-Vorrichtung nach Anspruch 8, ferner umfassend eine Fernstereinheit zur Fensterung des empfangenen Signals unter Verwendung einer Fensterungslänge, gewählt um Fenster mit einer Erwartung eines einzelnen Primärechos bereitzustellen.
- Ultraschall-Empfangsvorrichtung nach Anspruch 10, wobei der Signalprozessor ferner konfiguriert ist, einen Erscheinungspunkt eines Primärechos in einem empfangenen Signal zu finden durch aufeinanderfolgendes Dividieren der Kurve, Anpassen an eine lineare Funktion und Berechnen eines Punktes, an dem eine entsprechende Fehlerfunktion minimiert wird.
- Ultraschall-Empfangsvorrichtung nach Anspruch 11, ferner konfiguriert mit einer Lokalisierungseinheit zum Bestimmen eines Abstands zu einer ersten Merkmalswand von dem Erscheinungspunkt und konfiguriert zur Verwendung eines zweiten Erscheinungspunkts eines weiteren Primärechos zum Bestimmen eines Abstands zu einer weiteren Merkmalswand, wobei der Signalprozessor eine Überwachungseinheit zum Überwachen eines Abstands zwischen der ersten Merkmalswand und der zweiten Merkmalswand als ein Indikator des Ablösungsfortschritts umfasst.
- Ultraschallvorrichtung nach Anspruch 8, wobei der Signalprozessor eine Windungseinheit zum Falten eines Erregungssignals mit dem empfangenen Signal umfasst, um die Isolierung des Primärechos zu bewerkstelligen.
- Ultraschallvorrichtung nach Anspruch 8, ferner umfassend eine Referenz-Subtraktionseinheit, konfiguriert zum Subtrahieren einer Referenz von dem Transceiver-Signa durch Durchschnittsbestimmung mehrerer Signalproben.
- Vorrichtung nach einem der Ansprüche 1-14, wobei der Ultraschall-Ablösestrahl nicht fokussiert ist.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39394710P | 2010-10-18 | 2010-10-18 | |
US201161453239P | 2011-03-16 | 2011-03-16 | |
US13/049,022 US20120095371A1 (en) | 2010-10-18 | 2011-03-16 | Ultrasound transducer and cooling thereof |
PCT/IB2011/054639 WO2012052925A1 (en) | 2010-10-18 | 2011-10-18 | An ultrasound transceiver and control of a thermal damage process |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2629848A1 EP2629848A1 (de) | 2013-08-28 |
EP2629848B1 true EP2629848B1 (de) | 2014-10-08 |
Family
ID=44993632
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11782223.9A Active EP2629848B1 (de) | 2010-10-18 | 2011-10-18 | Ultraschall-transceiver und steuerung eines wärmeschadensprozesses |
EP11784782.2A Withdrawn EP2661304A1 (de) | 2010-10-18 | 2011-10-18 | Therapeutika-reservoir |
EP11833950.6A Active EP2629736B1 (de) | 2010-10-18 | 2011-10-18 | Gewebebehandlung |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11784782.2A Withdrawn EP2661304A1 (de) | 2010-10-18 | 2011-10-18 | Therapeutika-reservoir |
EP11833950.6A Active EP2629736B1 (de) | 2010-10-18 | 2011-10-18 | Gewebebehandlung |
Country Status (5)
Country | Link |
---|---|
US (4) | US20130218068A1 (de) |
EP (3) | EP2629848B1 (de) |
JP (1) | JP2013543423A (de) |
CN (1) | CN103298441A (de) |
WO (3) | WO2012052920A1 (de) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US20040082859A1 (en) | 2002-07-01 | 2004-04-29 | Alan Schaer | Method and apparatus employing ultrasound energy to treat body sphincters |
EP2021846B1 (de) | 2006-05-19 | 2017-05-03 | Koninklijke Philips N.V. | Ablationsvorrichtung mit optimiertem eingangsleistungsprofil |
US20080039746A1 (en) | 2006-05-25 | 2008-02-14 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
WO2011053757A1 (en) | 2009-10-30 | 2011-05-05 | Sound Interventions, Inc. | Method and apparatus for treatment of hypertension through percutaneous ultrasound renal denervation |
US20110112400A1 (en) * | 2009-11-06 | 2011-05-12 | Ardian, Inc. | High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation |
EP2629848B1 (de) | 2010-10-18 | 2014-10-08 | Cardiosonic Ltd. | Ultraschall-transceiver und steuerung eines wärmeschadensprozesses |
US8696581B2 (en) | 2010-10-18 | 2014-04-15 | CardioSonic Ltd. | Ultrasound transducer and uses thereof |
US9028417B2 (en) | 2010-10-18 | 2015-05-12 | CardioSonic Ltd. | Ultrasound emission element |
US9566456B2 (en) | 2010-10-18 | 2017-02-14 | CardioSonic Ltd. | Ultrasound transceiver and cooling thereof |
KR20230145213A (ko) | 2011-01-19 | 2023-10-17 | 프랙틸 헬쓰, 인코포레이티드 | 조직의 치료를 위한 장치 및 방법 |
JP6441679B2 (ja) | 2011-12-09 | 2018-12-19 | メタベンション インコーポレイテッド | 肝臓系の治療的な神経調節 |
CN104244856B (zh) * | 2011-12-23 | 2017-03-29 | 维西克斯血管公司 | 重建身体通道的组织或身体通路附近的组织的方法及设备 |
AU2013215164A1 (en) * | 2012-01-30 | 2014-08-14 | Vytronus, Inc. | Tissue necrosis methods and apparatus |
AU2013226062B2 (en) | 2012-02-27 | 2017-10-19 | Fractyl Health, Inc. | Heat ablation systems, devices and methods for the treatment of tissue |
US10357304B2 (en) | 2012-04-18 | 2019-07-23 | CardioSonic Ltd. | Tissue treatment |
JP6235559B2 (ja) | 2012-04-19 | 2017-11-22 | フラクティル ラボラトリーズ インコーポレイテッド | 組織拡張デバイス、システムおよび方法 |
CN104519817B (zh) | 2012-04-24 | 2017-11-10 | 西比姆公司 | 用于颈动脉体摘除的血管内导管和方法 |
CN104394933A (zh) * | 2012-04-27 | 2015-03-04 | 美敦力阿迪安卢森堡有限公司 | 肾神经调制的超声装置、系统、和方法 |
WO2013165935A1 (en) * | 2012-05-03 | 2013-11-07 | Sound Interventions, Inc. | Apparatus and method for uniform renal denervation |
US11357447B2 (en) | 2012-05-31 | 2022-06-14 | Sonivie Ltd. | Method and/or apparatus for measuring renal denervation effectiveness |
US9398930B2 (en) | 2012-06-01 | 2016-07-26 | Cibiem, Inc. | Percutaneous methods and devices for carotid body ablation |
US9402677B2 (en) | 2012-06-01 | 2016-08-02 | Cibiem, Inc. | Methods and devices for cryogenic carotid body ablation |
WO2014005155A1 (en) | 2012-06-30 | 2014-01-03 | Cibiem, Inc. | Carotid body ablation via directed energy |
EP3714826A1 (de) | 2012-07-30 | 2020-09-30 | Fractyl Laboratories, Inc. | Systeme und vorrichtungen zur ablation und behandlung von gewebe |
WO2014026055A1 (en) | 2012-08-09 | 2014-02-13 | Fractyl Laboratories Inc. | Ablation systems, devices and methods for the treatment of tissue |
US9060745B2 (en) | 2012-08-22 | 2015-06-23 | Covidien Lp | System and method for detecting fluid responsiveness of a patient |
US9357937B2 (en) | 2012-09-06 | 2016-06-07 | Covidien Lp | System and method for determining stroke volume of an individual |
US9241646B2 (en) | 2012-09-11 | 2016-01-26 | Covidien Lp | System and method for determining stroke volume of a patient |
US20140081152A1 (en) | 2012-09-14 | 2014-03-20 | Nellcor Puritan Bennett Llc | System and method for determining stability of cardiac output |
EP2903626A4 (de) | 2012-10-05 | 2016-10-19 | Fractyl Lab Inc | Verfahren, systeme und vorrichtungen zur durchführung mehrerer behandlungen eines patienten |
US9770593B2 (en) | 2012-11-05 | 2017-09-26 | Pythagoras Medical Ltd. | Patient selection using a transluminally-applied electric current |
EP2914192B1 (de) | 2012-11-05 | 2019-05-01 | Pythagoras Medical Ltd. | Gesteuerte gewebeablation |
US8977348B2 (en) | 2012-12-21 | 2015-03-10 | Covidien Lp | Systems and methods for determining cardiac output |
EP2971232A1 (de) | 2013-03-14 | 2016-01-20 | ReCor Medical, Inc. | Plattierungs- oder beschichtungsverfahren für ultraschallwandler |
US20140276615A1 (en) * | 2013-03-14 | 2014-09-18 | Volcano Corporation | Delivery catheter having imaging capabilities |
EP2968984B1 (de) | 2013-03-14 | 2016-08-17 | ReCor Medical, Inc. | Ultraschallbasiertes neuromodulationssystem |
WO2014153502A2 (en) * | 2013-03-21 | 2014-09-25 | Weinberg Medical Physics Llc | Apparatus and method for spatially selective interventional neuroparticles |
JP6440682B2 (ja) | 2013-03-28 | 2018-12-19 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | 集束超音波機器および使用方法 |
JP2016517750A (ja) * | 2013-05-02 | 2016-06-20 | ハリントン ダグラス シー.HARRINGTON, Douglas C. | 大動脈腎動脈神経節の検出と治療のための装置及び方法 |
WO2014188430A2 (en) | 2013-05-23 | 2014-11-27 | CardioSonic Ltd. | Devices and methods for renal denervation and assessment thereof |
WO2014189966A1 (en) * | 2013-05-24 | 2014-11-27 | New Star Lasers, Inc. A California Corporation | Sonic endovenous catheter |
EP3003461B1 (de) | 2013-06-04 | 2019-05-01 | Fractyl Laboratories, Inc. | Systeme und vorrichtungen zur reduzierung des lumenoberflächenbereichs des gastrointestinaltrakts |
WO2014197625A1 (en) | 2013-06-05 | 2014-12-11 | Metavention, Inc. | Modulation of targeted nerve fibers |
EP3003455B1 (de) | 2013-06-08 | 2023-08-30 | Lxs, Llc | Systeme zur durchführung medizinischer prozeduren mit zugriff auf das lymphsystem |
CN103330578B (zh) * | 2013-07-19 | 2015-05-27 | 乐普(北京)医疗器械股份有限公司 | 一种次圆周式超声消融导管 |
EP3043732B1 (de) | 2013-09-12 | 2021-04-07 | Fractyl Laboratories, Inc. | Systeme und vorrichtungen zur behandlung von zielgewebe |
KR102284469B1 (ko) | 2013-11-22 | 2021-08-02 | 프랙틸 헬쓰, 인코포레이티드 | 위장관에 치료 제한부를 생성하기 위한 시스템, 장치 및 방법 |
WO2015138795A1 (en) | 2014-03-12 | 2015-09-17 | Cibiem, Inc. | Carotid body ablation with a transvenous ultrasound imaging and ablation catheter |
US10959774B2 (en) | 2014-03-24 | 2021-03-30 | Fractyl Laboratories, Inc. | Injectate delivery devices, systems and methods |
CN106659531A (zh) | 2014-05-07 | 2017-05-10 | 毕达哥拉斯医疗有限公司 | 受控组织消融技术 |
US9757535B2 (en) | 2014-07-16 | 2017-09-12 | Fractyl Laboratories, Inc. | Systems, devices and methods for performing medical procedures in the intestine |
EP3169260B1 (de) | 2014-07-16 | 2019-09-25 | Fractyl Laboratories, Inc. | System zur behandlung von diabetes und zugehöriger erkrankungen und störungen |
US11185367B2 (en) | 2014-07-16 | 2021-11-30 | Fractyl Health, Inc. | Methods and systems for treating diabetes and related diseases and disorders |
US20180326227A1 (en) * | 2014-11-26 | 2018-11-15 | Sonievie Ltd. | Devices and methods for pulmonary hypertension treatment |
US10383685B2 (en) | 2015-05-07 | 2019-08-20 | Pythagoras Medical Ltd. | Techniques for use with nerve tissue |
EP3457975A2 (de) | 2016-05-18 | 2019-03-27 | Pythagoras Medical Ltd. | Spiralförmiger katheter |
EP3463573A2 (de) | 2016-06-06 | 2019-04-10 | Sofwave Medical Ltd. | Ultraschallwandler und -system |
US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
US11383106B2 (en) * | 2016-11-24 | 2022-07-12 | National Institute Of Advanced Industrial Science And Technology | Ultrasound therapy system |
US20180235576A1 (en) * | 2017-02-22 | 2018-08-23 | Covidien Lp | Ultrasound doppler and elastography for ablation prediction and monitoring |
EP3593189A1 (de) * | 2017-03-10 | 2020-01-15 | Heraeus Noblelight America LLC | Vorrichtung mit einem strahlungsemitter zum aufbringen von strahlung auf ein ziel und zugehöriges verfahren |
EP3600434A4 (de) | 2017-03-20 | 2021-01-06 | Sonievie Ltd. | Behandlung von pulmonaler hypertonie |
JP2020511290A (ja) * | 2017-03-20 | 2020-04-16 | コルフロウ セラペウティクス エージーCorflow Therapeutics Ag | 複合ステント再灌流システム |
CN111212606B (zh) * | 2017-08-15 | 2024-03-01 | 皇家飞利浦有限公司 | 频率可调谐血管内超声设备 |
US11883235B2 (en) * | 2017-08-15 | 2024-01-30 | Philips Image Guided Therapy Corporation | Phased array imaging and therapy intraluminal ultrasound device |
EP3459596A1 (de) * | 2017-09-26 | 2019-03-27 | Koninklijke Philips N.V. | Leistungseinstellung in einem magnetresonanzgeführten hochintensiven fokussierten ultraschall |
RU2702440C2 (ru) * | 2017-12-27 | 2019-10-08 | Федеральное государственное автономное научное учреждение "Центральный научно-исследовательский и опытно-конструкторский институт робототехники и технической кибернетики" (ЦНИИ РТК) | Устройство для лечения геморроя при непрерывном доплер-контроле |
JP2022525064A (ja) * | 2019-03-27 | 2022-05-11 | ソフウェイブ メディカル リミテッド | 超音波トランスデューサ及び皮膚処置システム |
US11786760B2 (en) * | 2019-12-10 | 2023-10-17 | GE Precision Healthcare LLC | Multi-beam neuromodulation techniques |
CN111855800B (zh) * | 2020-07-17 | 2022-04-01 | 西南科技大学 | 声学振动快速无损测定水果货架期或最佳食用期的方法 |
JP2023537515A (ja) * | 2020-08-11 | 2023-09-01 | ソレント・セラピューティクス・インコーポレイテッド | 神経切除による肺炎症性疾患の処置 |
CN116803216A (zh) | 2020-12-31 | 2023-09-22 | 苏维夫医疗有限公司 | 安装在多个印刷电路板上的多个超声波激励器的冷却 |
EP4108197A1 (de) | 2021-06-24 | 2022-12-28 | Gradient Denervation Technologies | Systeme zur behandlung von gewebe |
WO2023060199A1 (en) * | 2021-10-06 | 2023-04-13 | The Trustees Of Columbia University In The City Of New York | Method and integrated system for selective removal of defective cells and edematous fluids from the lung |
US20240108404A1 (en) * | 2022-10-04 | 2024-04-04 | Otsuka Medical Devices Co., Ltd. | Devices, methods and systems for renal denervation |
Family Cites Families (249)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4319580A (en) | 1979-08-28 | 1982-03-16 | The Board Of Regents Of The University Of Washington | Method for detecting air emboli in the blood in an intracorporeal blood vessel |
SE461203B (sv) | 1983-01-24 | 1990-01-22 | Svanholm Engineering Ab G | Foerfarande och anlaeggning foer framstaellning av element av gasbetong |
US5372138A (en) | 1988-03-21 | 1994-12-13 | Boston Scientific Corporation | Acousting imaging catheters and the like |
US5038789A (en) | 1989-09-28 | 1991-08-13 | Frazin Leon J | Method and device for doppler-guided retrograde catheterization |
US5226847A (en) | 1989-12-15 | 1993-07-13 | General Electric Company | Apparatus and method for acquiring imaging signals with reduced number of interconnect wires |
ATE164746T1 (de) | 1990-01-12 | 1998-04-15 | Metcal Inc | Thermische atherektomievorrichtung |
AU3727993A (en) | 1992-02-21 | 1993-09-13 | Diasonics Inc. | Ultrasound intracavity system for imaging therapy planning and treatment of focal disease |
EP0597463A3 (en) | 1992-11-13 | 1996-11-06 | Dornier Med Systems Inc | Thermotherapiesonde. |
US6537306B1 (en) | 1992-11-13 | 2003-03-25 | The Regents Of The University Of California | Method of manufacture of a transurethral ultrasound applicator for prostate gland thermal therapy |
SE502620C2 (sv) | 1993-02-26 | 1995-11-27 | Leif Nilsson | Urinkateter |
JP3860227B2 (ja) | 1993-03-10 | 2006-12-20 | 株式会社東芝 | Mriガイド下で用いる超音波治療装置 |
US5467251A (en) | 1993-10-08 | 1995-11-14 | Northern Telecom Limited | Printed circuit boards and heat sink structures |
US20020169394A1 (en) | 1993-11-15 | 2002-11-14 | Eppstein Jonathan A. | Integrated tissue poration, fluid harvesting and analysis device, and method therefor |
JPH07227394A (ja) | 1994-02-21 | 1995-08-29 | Olympus Optical Co Ltd | 超音波診断治療システム |
US5471988A (en) | 1993-12-24 | 1995-12-05 | Olympus Optical Co., Ltd. | Ultrasonic diagnosis and therapy system in which focusing point of therapeutic ultrasonic wave is locked at predetermined position within observation ultrasonic scanning range |
WO1995029737A1 (en) * | 1994-05-03 | 1995-11-09 | Board Of Regents, The University Of Texas System | Apparatus and method for noninvasive doppler ultrasound-guided real-time control of tissue damage in thermal therapy |
US5620417A (en) | 1994-07-07 | 1997-04-15 | Cardiovascular Imaging Systems Incorporated | Rapid exchange delivery catheter |
US8025661B2 (en) | 1994-09-09 | 2011-09-27 | Cardiofocus, Inc. | Coaxial catheter instruments for ablation with radiant energy |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
US5735280A (en) | 1995-05-02 | 1998-04-07 | Heart Rhythm Technologies, Inc. | Ultrasound energy delivery system and method |
US5895355A (en) | 1995-05-23 | 1999-04-20 | Cardima, Inc. | Over-the-wire EP catheter |
DE19520749C1 (de) | 1995-06-07 | 1996-08-08 | Siemens Ag | Therapiegerät mit einer Quelle akustischer Wellen |
JPH09122139A (ja) | 1995-10-31 | 1997-05-13 | Olympus Optical Co Ltd | 超音波治療装置 |
US5895356A (en) | 1995-11-15 | 1999-04-20 | American Medical Systems, Inc. | Apparatus and method for transurethral focussed ultrasound therapy |
US6073048A (en) | 1995-11-17 | 2000-06-06 | Medtronic, Inc. | Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure |
US7226417B1 (en) | 1995-12-26 | 2007-06-05 | Volcano Corporation | High resolution intravascular ultrasound transducer assembly having a flexible substrate |
US6261233B1 (en) | 1996-01-05 | 2001-07-17 | Sunlight Medical Ltd. | Method and device for a blood velocity determination |
US5800482A (en) | 1996-03-06 | 1998-09-01 | Cardiac Pathways Corporation | Apparatus and method for linear lesion ablation |
US5971949A (en) | 1996-08-19 | 1999-10-26 | Angiosonics Inc. | Ultrasound transmission apparatus and method of using same |
US8663311B2 (en) | 1997-01-24 | 2014-03-04 | Celonova Stent, Inc. | Device comprising biodegradable bistable or multistable cells and methods of use |
US5772642A (en) | 1997-02-19 | 1998-06-30 | Medtronic, Inc. | Closed end catheter |
JPH10248854A (ja) | 1997-03-11 | 1998-09-22 | Olympus Optical Co Ltd | 超音波治療装置 |
US6012457A (en) | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
FR2764516B1 (fr) | 1997-06-11 | 1999-09-03 | Inst Nat Sante Rech Med | Applicateur intratissulaire ultrasonore pour l'hyperthermie |
US6514249B1 (en) | 1997-07-08 | 2003-02-04 | Atrionix, Inc. | Positioning system and method for orienting an ablation element within a pulmonary vein ostium |
US6117101A (en) | 1997-07-08 | 2000-09-12 | The Regents Of The University Of California | Circumferential ablation device assembly |
US6652515B1 (en) | 1997-07-08 | 2003-11-25 | Atrionix, Inc. | Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall |
US6547788B1 (en) | 1997-07-08 | 2003-04-15 | Atrionx, Inc. | Medical device with sensor cooperating with expandable member |
US6538739B1 (en) | 1997-09-30 | 2003-03-25 | The Regents Of The University Of California | Bubble diagnostics |
US6500121B1 (en) | 1997-10-14 | 2002-12-31 | Guided Therapy Systems, Inc. | Imaging, therapy, and temperature monitoring ultrasonic system |
US6007499A (en) | 1997-10-31 | 1999-12-28 | University Of Washington | Method and apparatus for medical procedures using high-intensity focused ultrasound |
AU2209599A (en) | 1997-12-31 | 1999-07-19 | Pharmasonics, Inc. | Methods and systems for the inhibition of vascular hyperplasia |
US6077225A (en) | 1998-01-23 | 2000-06-20 | Hewlett-Packard Company | Ultrasound method for enhancing image presentation when contrast agents are used |
US6319241B1 (en) * | 1998-04-30 | 2001-11-20 | Medtronic, Inc. | Techniques for positioning therapy delivery elements within a spinal cord or a brain |
US6740082B2 (en) | 1998-12-29 | 2004-05-25 | John H. Shadduck | Surgical instruments for treating gastro-esophageal reflux |
US6042556A (en) | 1998-09-04 | 2000-03-28 | University Of Washington | Method for determining phase advancement of transducer elements in high intensity focused ultrasound |
JP4095729B2 (ja) | 1998-10-26 | 2008-06-04 | 株式会社日立製作所 | 治療用超音波装置 |
US6645147B1 (en) | 1998-11-25 | 2003-11-11 | Acuson Corporation | Diagnostic medical ultrasound image and system for contrast agent imaging |
US6607502B1 (en) | 1998-11-25 | 2003-08-19 | Atrionix, Inc. | Apparatus and method incorporating an ultrasound transducer onto a delivery member |
US6296619B1 (en) | 1998-12-30 | 2001-10-02 | Pharmasonics, Inc. | Therapeutic ultrasonic catheter for delivering a uniform energy dose |
US6855123B2 (en) | 2002-08-02 | 2005-02-15 | Flow Cardia, Inc. | Therapeutic ultrasound system |
EP1769759B1 (de) | 1999-05-11 | 2008-08-13 | Atrionix, Inc. | Vorrichtung zur Ultraschallablation |
US6217530B1 (en) | 1999-05-14 | 2001-04-17 | University Of Washington | Ultrasonic applicator for medical applications |
US7778688B2 (en) | 1999-05-18 | 2010-08-17 | MediGuide, Ltd. | System and method for delivering a stent to a selected position within a lumen |
US6890332B2 (en) | 1999-05-24 | 2005-05-10 | Csaba Truckai | Electrical discharge devices and techniques for medical procedures |
FR2794961B1 (fr) | 1999-06-16 | 2001-09-21 | Global Link Finance | Procede de determination du decalage temporel entre les instants de passage d'une meme onde de pouls en deux points de mesure distincts d'un reseau arteriel d'un etre vivant et d'estimation de sa pression aortique |
US6235024B1 (en) | 1999-06-21 | 2001-05-22 | Hosheng Tu | Catheters system having dual ablation capability |
US6471694B1 (en) | 2000-08-09 | 2002-10-29 | Cryogen, Inc. | Control system for cryosurgery |
US7510536B2 (en) | 1999-09-17 | 2009-03-31 | University Of Washington | Ultrasound guided high intensity focused ultrasound treatment of nerves |
US6652547B2 (en) | 1999-10-05 | 2003-11-25 | Omnisonics Medical Technologies, Inc. | Apparatus and method of removing occlusions using ultrasonic medical device operating in a transverse mode |
US6695782B2 (en) | 1999-10-05 | 2004-02-24 | Omnisonics Medical Technologies, Inc. | Ultrasonic probe device with rapid attachment and detachment means |
US20040097996A1 (en) | 1999-10-05 | 2004-05-20 | Omnisonics Medical Technologies, Inc. | Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode |
US20050240170A1 (en) | 1999-10-25 | 2005-10-27 | Therus Corporation | Insertable ultrasound probes, systems, and methods for thermal therapy |
WO2001030240A1 (en) | 1999-10-27 | 2001-05-03 | Neuroscience Toolworks, Inc. | Sonar-controlled apparatus for the delivery of electromagnetic radiation |
US6626855B1 (en) | 1999-11-26 | 2003-09-30 | Therus Corpoation | Controlled high efficiency lesion formation using high intensity ultrasound |
WO2001041655A1 (en) | 1999-12-06 | 2001-06-14 | Simcha Milo | Ultrasonic medical device |
WO2001045550A2 (en) | 1999-12-23 | 2001-06-28 | Therus Corporation | Ultrasound transducers for imaging and therapy |
US7166098B1 (en) | 1999-12-30 | 2007-01-23 | Advanced Cardiovascular Systems, Inc. | Medical assembly with transducer for local delivery of a therapeutic substance and method of using same |
US6451013B1 (en) | 2000-01-19 | 2002-09-17 | Medtronic Xomed, Inc. | Methods of tonsil reduction using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US8221402B2 (en) | 2000-01-19 | 2012-07-17 | Medtronic, Inc. | Method for guiding a medical device |
US6457365B1 (en) | 2000-02-09 | 2002-10-01 | Endosonics Corporation | Method and apparatus for ultrasonic imaging |
US20020048310A1 (en) | 2000-03-07 | 2002-04-25 | Heuser Richard R. | Catheter for thermal and ultrasound evaluation of arteriosclerotic plaque |
US6428477B1 (en) | 2000-03-10 | 2002-08-06 | Koninklijke Philips Electronics, N.V. | Delivery of theraputic ultrasound by two dimensional ultrasound array |
US6605084B2 (en) | 2000-03-24 | 2003-08-12 | Transurgical, Inc. | Apparatus and methods for intrabody thermal treatment |
US7025765B2 (en) * | 2000-03-31 | 2006-04-11 | Rita Medical Systems, Inc. | Tissue biopsy and treatment apparatus and method |
EP1296598B1 (de) | 2000-05-16 | 2007-11-14 | Atrionix, Inc. | Gerät mit einem ultraschallwandlers auf einem zuführungsstück |
AU6682401A (en) | 2000-06-13 | 2001-12-24 | Atrionix Inc | Surgical ablation probe for forming a circumferential lesion |
CA2415134C (en) | 2000-07-13 | 2015-09-22 | Transurgical, Inc. | Thermal treatment methods and apparatus with focused energy application |
EP1299038B1 (de) | 2000-07-13 | 2013-01-09 | ReCor Medical, Inc. | Energieanwendung mit aufblasbarer, ringförmiger linse |
GB2365127A (en) | 2000-07-20 | 2002-02-13 | Jomed Imaging Ltd | Catheter |
SG105459A1 (en) | 2000-07-24 | 2004-08-27 | Micron Technology Inc | Mems heat pumps for integrated circuit heat dissipation |
US6740040B1 (en) | 2001-01-30 | 2004-05-25 | Advanced Cardiovascular Systems, Inc. | Ultrasound energy driven intraventricular catheter to treat ischemia |
US6932771B2 (en) | 2001-07-09 | 2005-08-23 | Civco Medical Instruments Co., Inc. | Tissue warming device and method |
US6763722B2 (en) | 2001-07-13 | 2004-07-20 | Transurgical, Inc. | Ultrasonic transducers |
US7285116B2 (en) | 2004-05-15 | 2007-10-23 | Irvine Biomedical Inc. | Non-contact tissue ablation device and methods thereof |
US8974446B2 (en) | 2001-10-11 | 2015-03-10 | St. Jude Medical, Inc. | Ultrasound ablation apparatus with discrete staggered ablation zones |
US8419729B2 (en) | 2001-12-04 | 2013-04-16 | Endoscopic Technologies, Inc. | Cardiac ablation devices and methods |
DE60226635D1 (de) | 2001-12-14 | 2008-06-26 | Monteris Medical Inc | Hyperthermiebehandlung und dazugehörige sonde |
US6998898B2 (en) | 2002-02-11 | 2006-02-14 | Texas Instruments Incorporated | Programmable front end for a receiving channel |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US7653438B2 (en) * | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US20030199747A1 (en) | 2002-04-19 | 2003-10-23 | Michlitsch Kenneth J. | Methods and apparatus for the identification and stabilization of vulnerable plaque |
US20030199768A1 (en) | 2002-04-19 | 2003-10-23 | Cespedes Eduardo Ignacio | Methods and apparatus for the identification and stabilization of vulnerable plaque |
US9439714B2 (en) | 2003-04-29 | 2016-09-13 | Atricure, Inc. | Vacuum coagulation probes |
US20040082859A1 (en) | 2002-07-01 | 2004-04-29 | Alan Schaer | Method and apparatus employing ultrasound energy to treat body sphincters |
US20130197555A1 (en) | 2002-07-01 | 2013-08-01 | Recor Medical, Inc. | Intraluminal devices and methods for denervation |
US6866662B2 (en) | 2002-07-23 | 2005-03-15 | Biosense Webster, Inc. | Ablation catheter having stabilizing array |
US6942677B2 (en) | 2003-02-26 | 2005-09-13 | Flowcardia, Inc. | Ultrasound catheter apparatus |
US7074188B2 (en) | 2002-08-26 | 2006-07-11 | The Cleveland Clinic Foundation | System and method of characterizing vascular tissue |
US7220233B2 (en) | 2003-04-08 | 2007-05-22 | Flowcardia, Inc. | Ultrasound catheter devices and methods |
US20060052774A1 (en) | 2002-09-20 | 2006-03-09 | Garrison David M | Electrosurgical instrument for fragmenting, cutting and coagulating tissue |
EP1539291A4 (de) | 2002-09-20 | 2010-03-10 | Flowmedica Inc | Verfahren und gerät für die selektive materialabgabe über einen intrarenalen katheter |
US7156816B2 (en) | 2002-11-26 | 2007-01-02 | Biosense, Inc. | Ultrasound pulmonary vein isolation |
CA2412856A1 (en) | 2002-11-27 | 2004-05-27 | Frederic Bodin | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
WO2004054448A1 (en) | 2002-12-18 | 2004-07-01 | Koninklijke Philips Electronics N.V. | Ultrasonic doppler system for determining movement of artery walls |
US7771372B2 (en) | 2003-01-03 | 2010-08-10 | Ekos Corporation | Ultrasonic catheter with axial energy field |
US8021359B2 (en) * | 2003-02-13 | 2011-09-20 | Coaptus Medical Corporation | Transseptal closure of a patent foramen ovale and other cardiac defects |
JP2004290462A (ja) | 2003-03-27 | 2004-10-21 | Terumo Corp | アプリケータの最適位置提示システム |
US7220258B2 (en) | 2003-07-02 | 2007-05-22 | Cancercure As | Therapeutic probe, method and system |
JP2005027907A (ja) | 2003-07-07 | 2005-02-03 | Olympus Corp | 超音波手術システムおよびプローブ |
US7678104B2 (en) | 2003-07-17 | 2010-03-16 | Biosense Webster, Inc. | Ultrasound ablation catheter and method for its use |
DE202004021951U1 (de) | 2003-09-12 | 2013-06-19 | Vessix Vascular, Inc. | Auswählbare exzentrische Remodellierung und/oder Ablation von atherosklerotischem Material |
US7347859B2 (en) | 2003-12-18 | 2008-03-25 | Boston Scientific, Scimed, Inc. | Tissue treatment system and method for tissue perfusion using feedback control |
DE602004032574D1 (de) | 2003-12-31 | 2011-06-16 | Biosense Webster Inc | Umfangsmässige ablationsvorrichtungsanordnung mit dualen expandierbaren elementen |
WO2005072409A2 (en) | 2004-01-29 | 2005-08-11 | Ekos Corporation | Method and apparatus for detecting vascular conditions with a catheter |
US7727228B2 (en) | 2004-03-23 | 2010-06-01 | Medtronic Cryocath Lp | Method and apparatus for inflating and deflating balloon catheters |
US7854733B2 (en) | 2004-03-24 | 2010-12-21 | Biosense Webster, Inc. | Phased-array for tissue treatment |
CN1942145A (zh) | 2004-04-19 | 2007-04-04 | 普罗里森姆股份有限公司 | 带传感器结构的消融装置 |
US20070222339A1 (en) | 2004-04-20 | 2007-09-27 | Mark Lukacs | Arrayed ultrasonic transducer |
US7313442B2 (en) | 2004-04-30 | 2007-12-25 | Advanced Neuromodulation Systems, Inc. | Method of treating mood disorders and/or anxiety disorders by brain stimulation |
US7538425B2 (en) | 2004-07-28 | 2009-05-26 | Delphi Technologies, Inc. | Power semiconductor package having integral fluid cooling |
EP1799302B1 (de) | 2004-07-28 | 2015-03-04 | Ardian, Inc. | Vorrichtungen für die nierennervenblockade |
US7540852B2 (en) | 2004-08-26 | 2009-06-02 | Flowcardia, Inc. | Ultrasound catheter devices and methods |
US7824348B2 (en) | 2004-09-16 | 2010-11-02 | Guided Therapy Systems, L.L.C. | System and method for variable depth ultrasound treatment |
US8535228B2 (en) * | 2004-10-06 | 2013-09-17 | Guided Therapy Systems, Llc | Method and system for noninvasive face lifts and deep tissue tightening |
US7479106B2 (en) | 2004-09-30 | 2009-01-20 | Boston Scientific Scimed, Inc. | Automated control of irrigation and aspiration in a single-use endoscope |
KR20070106972A (ko) | 2004-10-06 | 2007-11-06 | 가이디드 테라피 시스템스, 엘.엘.씨. | 초음파 조직치료용 시스템 및 방법 |
EP2279698A3 (de) * | 2004-10-06 | 2014-02-19 | Guided Therapy Systems, L.L.C. | Verfahren und System zur nicht invasiven kosmetischen Verbesserung von Dehnstreifen |
US7883506B2 (en) | 2004-11-08 | 2011-02-08 | Boston Scientific Scimed, Inc. | Devices and methods for the treatment of endometriosis |
US7713210B2 (en) | 2004-11-23 | 2010-05-11 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and apparatus for localizing an ultrasound catheter |
US20060173387A1 (en) | 2004-12-10 | 2006-08-03 | Douglas Hansmann | Externally enhanced ultrasonic therapy |
US20060135953A1 (en) | 2004-12-22 | 2006-06-22 | Wlodzimierz Kania | Tissue ablation system including guidewire with sensing element |
CA2604380A1 (en) | 2005-04-12 | 2006-10-19 | Ekos Corporation | Ultrasound catheter with cavitation promoting surface |
JP2006289098A (ja) | 2005-04-12 | 2006-10-26 | Inolase 2002 Ltd | 皮膚の真空援用式光ベース治療用の装置 |
US7850683B2 (en) | 2005-05-20 | 2010-12-14 | Myoscience, Inc. | Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat) |
EP1895927A4 (de) | 2005-06-20 | 2011-03-09 | Medtronic Ablation Frontiers | Ablationskatheter |
US7819868B2 (en) | 2005-06-21 | 2010-10-26 | St. Jude Medical, Atrial Fibrilation Division, Inc. | Ablation catheter with fluid distribution structures |
US7628789B2 (en) | 2005-08-17 | 2009-12-08 | Pulmonx Corporation | Selective lung tissue ablation |
JP4402629B2 (ja) | 2005-08-19 | 2010-01-20 | オリンパスメディカルシステムズ株式会社 | 超音波凝固切開装置 |
US20090093737A1 (en) | 2007-10-09 | 2009-04-09 | Cabochon Aesthetics, Inc. | Ultrasound apparatus with treatment lens |
US20070142879A1 (en) | 2005-12-20 | 2007-06-21 | The Cleveland Clinic Foundation | Apparatus and method for modulating the baroreflex system |
US20070088346A1 (en) | 2005-10-14 | 2007-04-19 | Mirizzi Michael S | Method and apparatus for varicose vein treatment using acoustic hemostasis |
US7864129B2 (en) | 2006-04-04 | 2011-01-04 | Namiki Seimitsu Houseki Kabushiki Kaisha | Radio frequency medical treatment device and system and usage method thereof |
WO2007115307A2 (en) | 2006-04-04 | 2007-10-11 | Volcano Corporation | Ultrasound catheter and hand-held device for manipulating a transducer on the catheter's distal end |
WO2007127176A2 (en) | 2006-04-24 | 2007-11-08 | Ekos Corporation | Ultrasound therapy system |
EP2021846B1 (de) | 2006-05-19 | 2017-05-03 | Koninklijke Philips N.V. | Ablationsvorrichtung mit optimiertem eingangsleistungsprofil |
US7704212B2 (en) | 2006-06-14 | 2010-04-27 | Spacelabs Healthcare | Reusable invasive fluid pressure monitoring apparatus and method |
ATE536147T1 (de) | 2006-06-28 | 2011-12-15 | Ardian Inc | Systeme für wärmeinduzierte renale neuromodulation |
US8504132B2 (en) | 2006-06-28 | 2013-08-06 | Paul Friedman | Methods and apparatus for assessing and improving electrode contact with cardiac tissue |
EP2073884B1 (de) | 2006-08-02 | 2018-10-10 | Osprey Medical Inc. | Detektion und therapie mikrovaskulärer verstopfungen |
US20090221955A1 (en) | 2006-08-08 | 2009-09-03 | Bacoustics, Llc | Ablative ultrasonic-cryogenic methods |
US20080039727A1 (en) | 2006-08-08 | 2008-02-14 | Eilaz Babaev | Ablative Cardiac Catheter System |
US20080195000A1 (en) | 2006-09-06 | 2008-08-14 | Spooner Gregory J R | System and Method for Dermatological Treatment Using Ultrasound |
US20080183110A1 (en) | 2006-09-06 | 2008-07-31 | Davenport Scott A | Ultrasound system and method for hair removal |
US8192474B2 (en) | 2006-09-26 | 2012-06-05 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
US8728073B2 (en) | 2006-10-10 | 2014-05-20 | Biosense Webster, Inc. | Multi-region staged inflation balloon |
WO2008045877A2 (en) | 2006-10-10 | 2008-04-17 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Electrode tip and ablation system |
GB0622451D0 (en) | 2006-11-10 | 2006-12-20 | Intelligent Earth Ltd | Object position and orientation detection device |
US7775994B2 (en) | 2006-12-11 | 2010-08-17 | Emigrant Bank, N.A. | Ultrasound medical systems and related methods |
US8475375B2 (en) | 2006-12-15 | 2013-07-02 | General Electric Company | System and method for actively cooling an ultrasound probe |
US8382689B2 (en) | 2007-02-08 | 2013-02-26 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Device and method for high intensity focused ultrasound ablation with acoustic lens |
US8473030B2 (en) * | 2007-01-12 | 2013-06-25 | Medtronic Vascular, Inc. | Vessel position and configuration imaging apparatus and methods |
US8571662B2 (en) | 2007-01-29 | 2013-10-29 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
US8030754B2 (en) | 2007-01-31 | 2011-10-04 | Hewlett-Packard Development Company, L.P. | Chip cooling channels formed in wafer bonding gap |
EP2730247B1 (de) * | 2007-02-22 | 2017-04-26 | Ramot at Tel Aviv University Ltd. | Vorrichtung zur Behandlung von Blutgefässen |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
US9486651B2 (en) * | 2007-03-30 | 2016-11-08 | Koninklijke Philips N.V. | MRI-guided HIFU marking to guide radiotherapy and other procedures |
WO2008150871A1 (en) * | 2007-05-30 | 2008-12-11 | Critical Care Innovations, Inc. | Process and device for selectively treating interstitial tissue |
US7634315B2 (en) | 2007-05-31 | 2009-12-15 | Pacesetter, Inc. | Techniques to monitor and trend nerve damage and recovery |
US7460369B1 (en) | 2007-06-01 | 2008-12-02 | Advanced Micro Devices, Inc. | Counterflow microchannel cooler for integrated circuits |
US20090018446A1 (en) | 2007-07-10 | 2009-01-15 | Insightec, Ltd. | Transrectal ultrasound ablation probe |
US9044261B2 (en) | 2007-07-31 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Temperature controlled ultrasonic surgical instruments |
JP5014051B2 (ja) * | 2007-10-09 | 2012-08-29 | 株式会社ユネクス | 血管超音波画像測定方法 |
EP2214573B1 (de) | 2007-10-26 | 2019-07-03 | University Of Virginia Patent Foundation | System zur behandlung und bilddarstellung mit ultraschallenergie und mikrobläschen |
US8906011B2 (en) | 2007-11-16 | 2014-12-09 | Kardium Inc. | Medical device for use in bodily lumens, for example an atrium |
US20090149782A1 (en) * | 2007-12-11 | 2009-06-11 | Donald Cohen | Non-Invasive Neural Stimulation |
US20090163807A1 (en) | 2007-12-21 | 2009-06-25 | Sliwa John W | Finger-mounted or robot-mounted transducer device |
EP2092916A1 (de) * | 2008-02-19 | 2009-08-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Verfahren zur Behandlung einer Augenkrankheit durch Verabreichung hochintensiven fokussierten Ultraschalls und entsprechende Vorrichtung |
US7981092B2 (en) | 2008-05-08 | 2011-07-19 | Ethicon Endo-Surgery, Inc. | Vibratory trocar |
ES2398052T5 (es) | 2008-05-09 | 2021-10-25 | Nuvaira Inc | Sistemas para tratar un árbol bronquial |
US8133222B2 (en) | 2008-05-28 | 2012-03-13 | Medwaves, Inc. | Tissue ablation apparatus and method using ultrasonic imaging |
CN102149428B (zh) * | 2008-07-14 | 2015-07-08 | 代理并代表亚利桑那州立大学的亚利桑那董事会 | 使用超声用于调节细胞活性的方法和装置 |
US20100049099A1 (en) | 2008-07-18 | 2010-02-25 | Vytronus, Inc. | Method and system for positioning an energy source |
US8585695B2 (en) | 2008-07-22 | 2013-11-19 | Hue-Teh Shih | Systems and methods for noncontact ablation |
US20100036293A1 (en) | 2008-08-05 | 2010-02-11 | Scott Isola | HIFU treatment probe |
US9173047B2 (en) | 2008-09-18 | 2015-10-27 | Fujifilm Sonosite, Inc. | Methods for manufacturing ultrasound transducers and other components |
US20100114082A1 (en) | 2008-10-06 | 2010-05-06 | Sharma Virender K | Method and Apparatus for the Ablation of Endometrial Tissue |
KR20110104504A (ko) | 2008-11-17 | 2011-09-22 | 미노우 메디컬, 인코포레이티드 | 조직 토폴로지의 지식 여하에 따른 에너지의 선택적 축적 |
US8475379B2 (en) | 2008-11-17 | 2013-07-02 | Vytronus, Inc. | Systems and methods for ablating body tissue |
US9352174B2 (en) | 2008-12-30 | 2016-05-31 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Ablation system with blood leakage minimization and tissue protective capabilities |
US9108037B2 (en) | 2009-03-09 | 2015-08-18 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Apparatus and method for tissue ablation with near-field cooling |
US8540662B2 (en) | 2009-03-24 | 2013-09-24 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Medical devices having an atraumatic distal tip segment |
US20120116221A1 (en) * | 2009-04-09 | 2012-05-10 | The Trustees Of The University Of Pennsylvania | Methods and systems for image-guided treatment of blood vessels |
EP2421364A4 (de) | 2009-04-22 | 2012-10-17 | Mercator Medsystems Inc | Verwendung von guanethidin zur behandlung von bluthochdruck über lokale vaskuläre freisetzung |
JP5702780B2 (ja) | 2009-07-21 | 2015-04-15 | ユニバーシティ オブ バージニア パテント ファウンデーション | カテーテルシステム |
US20120123270A1 (en) | 2009-07-29 | 2012-05-17 | Koninklijke Philips Electronics N.V. | Device with integrated ultrasound transducers and flow sensor |
US20110028962A1 (en) | 2009-07-31 | 2011-02-03 | Randell Werneth | Adjustable pulmonary vein ablation catheter |
CA2774346C (en) | 2009-09-16 | 2019-08-20 | Board Of Regents, The University Of Texas System | Altering temperature in a mammalian body |
US9119951B2 (en) | 2009-10-12 | 2015-09-01 | Kona Medical, Inc. | Energetic modulation of nerves |
US20110092880A1 (en) * | 2009-10-12 | 2011-04-21 | Michael Gertner | Energetic modulation of nerves |
US8986211B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
US20140074076A1 (en) | 2009-10-12 | 2014-03-13 | Kona Medical, Inc. | Non-invasive autonomic nervous system modulation |
US20160059044A1 (en) | 2009-10-12 | 2016-03-03 | Kona Medical, Inc. | Energy delivery to intraparenchymal regions of the kidney to treat hypertension |
US9174065B2 (en) * | 2009-10-12 | 2015-11-03 | Kona Medical, Inc. | Energetic modulation of nerves |
US20110257563A1 (en) | 2009-10-26 | 2011-10-20 | Vytronus, Inc. | Methods and systems for ablating tissue |
WO2011053757A1 (en) | 2009-10-30 | 2011-05-05 | Sound Interventions, Inc. | Method and apparatus for treatment of hypertension through percutaneous ultrasound renal denervation |
WO2011053182A1 (ru) | 2009-11-02 | 2011-05-05 | Leontiev Vladimir Vasilievich | Устройство накопления и обработки информации (унои) |
US20110112400A1 (en) * | 2009-11-06 | 2011-05-12 | Ardian, Inc. | High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation |
EP2498705B1 (de) * | 2009-11-11 | 2014-10-15 | Holaira, Inc. | Vorrichtung zur gewebebehandlung und stenosekontrolle |
US9457171B2 (en) | 2009-12-02 | 2016-10-04 | Renovorx, Inc. | Devices, methods and kits for delivery of therapeutic materials to a target artery |
ES2928669T3 (es) | 2009-12-31 | 2022-11-22 | Zetroz Systems Llc | Dispositivo de acoplamiento para ecografía |
US20110201973A1 (en) | 2010-02-18 | 2011-08-18 | St. Jude Medical, Inc. | Ultrasound compatible radiofrequency ablation electrode |
JP5760079B2 (ja) | 2010-04-14 | 2015-08-05 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 腎動脈に除神経療法を送達する装置 |
US8834388B2 (en) * | 2010-04-30 | 2014-09-16 | Medtronic Ablation Frontiers Llc | Method and apparatus to regulate a tissue temperature |
US8617150B2 (en) * | 2010-05-14 | 2013-12-31 | Liat Tsoref | Reflectance-facilitated ultrasound treatment |
US20120053577A1 (en) | 2010-08-25 | 2012-03-01 | Neuwave Medical, Inc. | Energy delivery systems and uses thereof |
US9566456B2 (en) | 2010-10-18 | 2017-02-14 | CardioSonic Ltd. | Ultrasound transceiver and cooling thereof |
US9028417B2 (en) | 2010-10-18 | 2015-05-12 | CardioSonic Ltd. | Ultrasound emission element |
EP2629848B1 (de) | 2010-10-18 | 2014-10-08 | Cardiosonic Ltd. | Ultraschall-transceiver und steuerung eines wärmeschadensprozesses |
US8696581B2 (en) | 2010-10-18 | 2014-04-15 | CardioSonic Ltd. | Ultrasound transducer and uses thereof |
US20120215106A1 (en) | 2010-10-18 | 2012-08-23 | CardioSonic Ltd. | Tissue treatment |
US20130218054A1 (en) | 2010-10-18 | 2013-08-22 | CardioSonic Ltd. | Separation device for ultrasound element |
EP2455133A1 (de) | 2010-11-18 | 2012-05-23 | Koninklijke Philips Electronics N.V. | Katheter mit kapazitiven mikrobearbeiteten Ultraschall-Transducern mit einstellbarer Brennweite |
US20120232409A1 (en) | 2010-12-15 | 2012-09-13 | Stahmann Jeffrey E | System and method for renal artery occlusion during renal denervation therapy |
KR101862903B1 (ko) | 2011-08-26 | 2018-05-30 | 사이맵 홀딩 리미티드 | 동맥벽 기능성 신경의 위치 확정과 식별에 사용하는 카테터 및 그 사용 방법 |
WO2013111136A2 (en) | 2012-01-25 | 2013-08-01 | CardioSonic Ltd. | Selective reduction of nerve activity |
US20130225595A1 (en) | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis |
AU2013230893B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the management of pain |
WO2013157009A2 (en) | 2012-04-18 | 2013-10-24 | CardioSonic Ltd. | Tissue treatment |
US10357304B2 (en) | 2012-04-18 | 2019-07-23 | CardioSonic Ltd. | Tissue treatment |
CN104394933A (zh) | 2012-04-27 | 2015-03-04 | 美敦力阿迪安卢森堡有限公司 | 肾神经调制的超声装置、系统、和方法 |
US20130296646A1 (en) | 2012-05-02 | 2013-11-07 | Enigma Medical, Inc. | Non-invasive or minimally invasive paraspinal sympathetic ablation for the treatment of resistant hypertension |
CN104470454B (zh) | 2012-05-18 | 2018-06-08 | 努瓦拉公司 | 紧凑传送的肺部治疗系统和改善肺部功能的方法 |
US11357447B2 (en) | 2012-05-31 | 2022-06-14 | Sonivie Ltd. | Method and/or apparatus for measuring renal denervation effectiveness |
EP2900160A2 (de) | 2012-09-26 | 2015-08-05 | Boston Scientific Scimed, Inc. | Katheter mit einer rippen- und wirbelsäulenstruktur zum stützen mehrerer elektroden zur nierennervenablation |
CN102908191A (zh) | 2012-11-13 | 2013-02-06 | 陈绍良 | 多极同步肺动脉射频消融导管 |
US9827036B2 (en) | 2012-11-13 | 2017-11-28 | Pulnovo Medical (Wuxi) Co., Ltd. | Multi-pole synchronous pulmonary artery radiofrequency ablation catheter |
WO2014188430A2 (en) | 2013-05-23 | 2014-11-27 | CardioSonic Ltd. | Devices and methods for renal denervation and assessment thereof |
US20160374710A1 (en) | 2014-03-12 | 2016-12-29 | Yegor D. Sinelnikov | Carotid body ablation with a transvenous ultrasound imaging and ablation catheter |
US10537387B2 (en) | 2014-04-17 | 2020-01-21 | Digma Medical Ltd. | Methods and systems for blocking neural activity in an organ of a subject, preferably in the small intestine or the duodenum |
US20180326227A1 (en) | 2014-11-26 | 2018-11-15 | Sonievie Ltd. | Devices and methods for pulmonary hypertension treatment |
EP3600434A4 (de) | 2017-03-20 | 2021-01-06 | Sonievie Ltd. | Behandlung von pulmonaler hypertonie |
-
2011
- 2011-10-18 EP EP11782223.9A patent/EP2629848B1/de active Active
- 2011-10-18 JP JP2013534436A patent/JP2013543423A/ja active Pending
- 2011-10-18 CN CN2011800607413A patent/CN103298441A/zh active Pending
- 2011-10-18 EP EP11784782.2A patent/EP2661304A1/de not_active Withdrawn
- 2011-10-18 EP EP11833950.6A patent/EP2629736B1/de active Active
- 2011-10-18 WO PCT/IB2011/054634 patent/WO2012052920A1/en active Application Filing
- 2011-10-18 US US13/880,109 patent/US20130218068A1/en not_active Abandoned
- 2011-10-18 WO PCT/IB2011/054639 patent/WO2012052925A1/en active Application Filing
- 2011-10-18 WO PCT/IB2011/054640 patent/WO2012052926A2/en active Application Filing
- 2011-10-18 US US13/880,083 patent/US20130204242A1/en not_active Abandoned
- 2011-10-18 US US13/880,066 patent/US20130211396A1/en not_active Abandoned
-
2012
- 2012-04-18 US US13/449,539 patent/US10967160B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2012052926A2 (en) | 2012-04-26 |
WO2012052926A3 (en) | 2012-08-23 |
US20120265227A1 (en) | 2012-10-18 |
JP2013543423A (ja) | 2013-12-05 |
US20130218068A1 (en) | 2013-08-22 |
WO2012052920A1 (en) | 2012-04-26 |
EP2629848A1 (de) | 2013-08-28 |
CN103298441A (zh) | 2013-09-11 |
EP2661304A1 (de) | 2013-11-13 |
WO2012052925A1 (en) | 2012-04-26 |
US20130211396A1 (en) | 2013-08-15 |
US20130204242A1 (en) | 2013-08-08 |
EP2629736A2 (de) | 2013-08-28 |
EP2629736B1 (de) | 2017-02-22 |
US10967160B2 (en) | 2021-04-06 |
EP2629736A4 (de) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2629848B1 (de) | Ultraschall-transceiver und steuerung eines wärmeschadensprozesses | |
US7894874B2 (en) | Method and apparatus for enhancing the detecting and tracking of moving objects using ultrasound | |
US7611467B2 (en) | Method and apparatus for extracting an envelope curve of a spectrogram | |
KR101398948B1 (ko) | 진폭―위상 변조된 초음파를 이용한 점탄성 측정 | |
CN107616809B (zh) | 医学诊断超声中的组织表征 | |
JP4263943B2 (ja) | 超音波診断装置 | |
US20070043294A1 (en) | Automatic detection method of spectral Doppler blood flow velocity | |
US20130345565A1 (en) | Measuring Acoustic Absorption or Attenuation of Ultrasound | |
US8226559B2 (en) | Method and apparatus for real-time temperature measuring for high-intensity focused ultrasound(HIFU) therapy system | |
US8100832B2 (en) | Ultrasound diagnostic apparatus | |
US11850098B2 (en) | Method and device for measuring an ultrasound parameter of a viscoelastic medium | |
Vilkomerson et al. | Finding the peak velocity in a flow from its Doppler spectrum | |
Ricci et al. | An improved Doppler model for obtaining accurate maximum blood velocities | |
JPH07265304A (ja) | 動脈の分節を超音波エコーグラフィにより検出し特徴付ける方法および装置 | |
CN107106125B (zh) | 用于测量动脉参数的系统和方法 | |
Ikeshita et al. | Noninvasive measurement of transient change in viscoelasticity due to flow-mediated dilation using automated detection of arterial wall boundaries | |
JPWO2006088094A1 (ja) | 超音波ドプラ血流計 | |
JP2010069065A (ja) | 非侵襲血糖測定装置 | |
Ibrahim et al. | Detection of arterial wall boundaries using an echo model composed of multiple ultrasonic pulses | |
US11751851B2 (en) | Methods, systems and computer program products for tissue analysis using ultrasonic backscatter coherence | |
Robles et al. | Ultrasonic bone localization algorithm based on time-series cumulative kurtosis | |
JP2007090003A (ja) | 超音波診断装置及びその制御方法 | |
KR20200143285A (ko) | 점탄성 매체의 초음파 파라미터를 측정하는 방법 및 디바이스 | |
Hasegawa et al. | Reduction of influence of decrease in signal-to-noise ratio in measurement of change in thickness of arterial wall due to heartbeat | |
Numata et al. | Basic study on detection of outer boundary of arterial wall using its longitudinal motion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130516 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 25/10 20130101ALN20140401BHEP Ipc: G01N 29/46 20060101ALN20140401BHEP Ipc: G01N 29/44 20060101ALN20140401BHEP Ipc: A61B 17/00 20060101ALN20140401BHEP Ipc: A61N 7/00 20060101AFI20140401BHEP Ipc: A61M 25/00 20060101ALI20140401BHEP |
|
INTG | Intention to grant announced |
Effective date: 20140424 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 690284 Country of ref document: AT Kind code of ref document: T Effective date: 20141015 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011010499 Country of ref document: DE Effective date: 20141120 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20141008 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 690284 Country of ref document: AT Kind code of ref document: T Effective date: 20141008 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150208 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150209 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150108 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150109 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011010499 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
26N | No opposition filed |
Effective date: 20150709 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141018 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20111018 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141008 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602011010499 Country of ref document: DE Owner name: SONIVIE LTD., IL Free format text: FORMER OWNER: CARDIOSONIC LTD., TEL-AVIV, IL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20210617 AND 20210623 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231005 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231020 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231025 Year of fee payment: 13 Ref country code: DE Payment date: 20231020 Year of fee payment: 13 |